ABSTRACT

Human morbidity and mortality associated with the infection SARS-CoV-2 is mainly due to pneumonia. The histological pattern of lungs is characterized by diffuse alveolar damage (DAD) and hyaline membranes. Vascular changes, including endothelial dysfunction in the alveolar septal capillaries followed by thrombosis and disseminated intravascular coagulation, are frequently associated. Recently, further microvascular changes leading to new blood vessel growth through intussusceptive angiogenesis and distortion of microvascular architecture have been reported in lungs from patients died because of COVID-19. Here we report a case of COVID-19 in a 63-year-old patient affected by progressive respiratory failure. At histology, DAD was associated with distinctive vascular chang-
es, including alveolar capillary microthrombi and thrombosis of arterial vessels. Moreover, a marked proliferation of small capillaries extending from the alveolar septa and compressing the adjacent alveoli was observed, allowing the diagnosis of pulmonary capillary hemangiomatosis (PCH). This report of PCH in a patient affected by COVID-19 reinforces the hypothesis of the major role played by endothelial dysfunction, capillary thrombosis and neoangiogenesis in SARS-CoV-2 infection and suggests that new blood vessel growth may evolve toward PCH, ending to the disruption of lung architecture.

**KEY WORDS**
Pulmonary capillary angiomatosis; COVID-19; SARS-CoV2.

**IMPACT STATEMENT**
Endothelial dysfunction, capillary thrombosis and neoangiogenesis with new blood vessel growth induced by SARS-CoV-2 may evolve toward pulmonary capillary hemangiomatosis and lung architecture disruption.

**INTRODUCTION**

Human morbidity and mortality associated with infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is mainly due to progressive life-threatening pneumonia (1, 2). At imaging assessment, computed tomography (CT) imaging evidences peripheral ground-glass opacities indicative for the diagnosis of acute respiratory distress syndrome (ARDS) (3). The histological pattern of lungs, at autopsy, is characterized by necrosis of alveolar lining cells (type I pneumocytes), hyaline membranes, alveolar and interstitial edema and hemorrhages, i.e. the typical features of diffuse alveolar damage (DAD) (4, 5).

However, lung pathology in COVID-19 patients is not restricted to alveolar damage: vascular changes are frequently associated with severe SARS-CoV-2 infection. Pulmonary thrombosis and disseminated intravascular coagulation, evidenced at histology by the formation of fibrin thrombi in the alveolar septa capillaries, are frequently detected in COVID-19 lung disease (6, 7). Recently, microvascular changes have been described in lungs from patients died from COVID-19, leading to new blood vessel formation, ending with distortion of the microvascular architecture of the lungs (8). By the use of scanning electron microscopy (SEM), structurally deformed capillaries were found in COVID-19 lungs, whereas transmission electron microscopy (TEM) revealed severe changes in endothelial cells in lungs from patients died from ARDS secondary to SARS-CoV-2 infection (9).

All these data taken together, vascular changes, including endothelial injury, widespread thrombosis of alveolar capillaries and new vessel growth, have been proposed as distinctive features of DAD due to SARS-CoV-2 infection, being absent in DAD associated with other etiologies (8). A recent proteomic analysis of 144 autopsies in COVID-19 patients evidenced dysregulation in multiple organs of key factors involved in angiogenesis, with 139 angiogenesis-related proteins significantly dysregulated that characterize a multi-organ proteomic landscape typical of COVID-19 (10).

Here we report a case of diffuse alveolar damage in a patient died with COVID-19, associated with a marked capillary proliferation leading to a pattern of pulmonary capillary hemangiomatosis (PCH).

**Case report**

A male patient, aged 63 years, developed a progressive respiratory failure. The patient died at home before medical intervention. Post-mortem molecular tests, performed by nasopharyngeal swabs, revealed SARS-CoV-2 infection. At autopsy, lungs were heavy (right lung 1,100 g; left lung 920 g), reddish in colour, diffusely edematous and showed a firm consistency. Microscopic examination of the lungs evidenced diffuse alveolar damage in the acute stage. Hyaline membranes were associated with marked congestion of larger veins and septal capillaries, alveolar and interstitial edema, fibro-hemorrhagic alveolitis and focal type II pneumocyte hyperplasia (figure 1). Lymphocyte and monocyte infiltrations were mild and patchy. In multiple lung specimens, distinctive vascular changes were also detected,
Figure 1. Diffuse alveolar damage. Hyaline membranes, hemorrhagic alveolitis, congestion of septa capillaries, type II pneumocyte hyperplasia.

Figure 2. Thrombosis of an arterial vessel surrounded by marked capillary proliferation and alveolar collapse.

Figure 3. Marked proliferation of capillary vessels, extending from the inter-alveolar septa into the surrounding alveolar and vascular structures.

Figure 4. a. Residual alveoli surrounded and infiltrated by proliferating capillaries at low power. b. At high power.
consisting in alveolar capillary microthrombi and thrombosis of arterial vessels (figure 2). Moreover, in some lung specimens we observed a marked proliferation of small capillaries, extending from the alveolar septa and compressing the adjacent alveolar structures (figure 3). The lumen of the proliferating capillaries was occupied by microthrombi. The disordered capillary proliferation irregularly spread, involving pre-existing pulmonary vessels and adjacent airways (figures 4 a, b). At immunohistochemistry, proliferating vascular structures showed strong and diffuse immunostaining for CD31, CD34 and focal immunoreactivity for WT1.

**DISCUSSION**

The complexity of pathological changes observed in the lungs of patients affected by COVID-19 has been recently underlined by multiple reports on the different molecular pathways triggered by SARS-CoV-2 (11). Among them, vascular changes of lung vasculature, including endothelial cell dysfunction, endothelialitis (12), thrombosis of septal capillaries (13) and thrombosis of pulmonary arteries (14) have been proposed as distinguishing elementary lesions of COVID-19 from ARDS due to influenza infection (14). Moreover, previous papers evidenced the occurrence, in lungs from patients infected by SARS-CoV-2, of new vessel growth through a mechanism of intussusceptive angiogenesis (14). Neoangiogenesis was hypothesized to be the consequence of tissue hypoxia, caused by the high degree of endothelial damage and capillary thrombosis due to SARS-CoV-2 infection.

In the case reported here, the hypothesis that pulmonary vessels represent one of the main targets for COVID-19 is confirmed by the detection of widespread lesions of endothelium, associated with diffuse intravascular coagulation in all the segments of lung vasculature. Moreover, our findings lay stress on the ability of SARS-CoV-2 to trigger a previously unreported proliferation of lung capillaries. In this case of lung disease due to COVID-19, proliferating vascular structures extended from the alveolar septa, infiltrating the structures of the pulmonary parenchyma, including alveoli, veins, and interstitial structures. These findings were at the basis of the diagnosis of pulmonary capillary hemangiomatosis (PCH), a rare and controversial entity often associated with pulmonary hypertension (15, 16). The underlying pathogenetic mechanisms of PCH are poorly understood. Recently, intussusceptive angiogenesis, a process of dividing pre-existing capillaries by formation of intravascular pillars, has been hypothesized to be involved in the pathogenesis of PCH (17). According to this hypothesis, venous and capillary occlusion, caused by a widespread thrombosis favoured by SARS-CoV-2 infection, might increase stretching forces in pulmonary capillaries, inducing intussusceptive neoangiogenesis, ending with the insurgence of PCH in COVID-19 pneumonia.

In conclusion, our report of PCH in a patient affected by COVID-19 reinforces previous reports on the major role played by endothelial dysfunction (18), endothelialitis, thrombosis (8) and neoangiogenesis (14) in lung disease due to SARS-CoV-2 infection, and suggests that SARS-CoV-2 induced neoangiogenesis may evolve toward capillary hemangiomatosis, ending with disruption of the lung architecture, a typical feature of PCH.

**ETHICS STATEMENT**

(i) Informed, written consent has not been obtained because the patient was dead; (ii) studies have been performed according to the Declaration of Helsinki; (iii) the procedures have been approved by a local ethics committee (date: 27/02/2021; approval number/code: PG/2021/1531; name of the ethics approving committee: Comitato Etico Indipendente Azienda Ospedaliero Universitaria di Cagliari).

**CONFLICT OF INTERESTS**

The authors have declared no conflict of interests.
REFERENCES


